Pharmaceutical compositions and methods for improving wrinkles and other skin conditions

ABSTRACT

This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and rebuild skin. In one preferred form, the composition further includes a catechin-based preparation, a glucosamine or a pharmaceutically acceptable salt or ester thereof, and a chondroitin or a pharmaceutically acceptable salt or ester thereof. In a more preferred form, the invention further includes a vitamin E source, a cysteine source, a vitamin B 3  source, quercetin dihydrate, pyridoxal 5 phosphate-Co B 6 , a methionine source, and a vitamin A source. The invention further relates to a method for the prevention or treatment of skin conditions by administering the pharmaceutical composition in an amount therapeutically effective to modify the thickness of the skin to prevent or treat at least one skin condition.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of application Ser. No. 08/787,358,filed Jan. 22,1997 U.S. Pat. No. 5,804,594.

TECHNICAL FIELD

This application relates to pharmaceutical compositions, as well asmethods, to supplement collagen and elastic tissues and thicken thedermis for the treatment of wrinkles and other skin conditions.

BACKGROUND OF THE INVENTION

Human skin is a composite material of the epidermis and the dermis. Thetopmost part of the epidermis is the stratum corneum. This layer is thestiffest layer of the skin, as well as the one most affected by thesurrounding environment. Below the stratum corneum is the internalportion of the epidermis. Below the epidermis, the topmost layer of thedermis is the papillary dermis, which is made of relatively looseconnective tissues that define the micro-relief of the skin. Thereticular dermis, disposed beneath the papillary dermis, is tight,connective tissue that is spatially organized. The reticular dermis isalso associated with coarse wrinkles. At the bottom of the dermis liesthe subcutaneous layer.

The principal functions of the skin include protection, excretion,secretion, absorption, thermoregulation, pigmentogenesis, accumulation,sensory perception, and regulation of immunological processes. Thesefunctions are detrimentally affected by the structural changes in theskin due to aging and excessive sun exposure. The physiological changesassociated with skin aging include impairment of the barrier functionand decreased turnover of epidermal cells, for example. [Cerimele, D.,et al., Br. J. Dermatol., 122 Suppl. 35, p. 13-20 (April 1990)].

The mechanical properties of the skin, such as elasticity, arecontrolled by the density and geometry of the network of collagen andelastic fiber tissue therein. Damaged collagen and elastin lose theircontractile properties, resulting in skin wrinkling and skin surfaceroughness. As the skin ages or becomes unhealthy, it acquires sags,stretch marks, bumps, bruises or wrinkles, it roughens, and it hasreduced ability to synthesize Vitamin D. Aged skin also becomes thinnerand has a flattened dermoepidermal interface because of the alterationsin collagen, elastin, and glycosaminoglycans. [Fenske, N. A, and Lober,C. W., J. Am. Acad. Dermatol., 15:571-585 (Oct. 1986); Montagna, W. andCarlisle, K., Journal of Investigative Dermatol., 73(1):47-53 (1979)].

A variety of vitamins and minerals have in individually beenadministered to treat certain skin and other problems that occur whenthe patient has a deficiency of that vitamin or mineral. Vitamin A, forexample, assists in the treatment of acne and to facilitate woundhealing; vitamin C (ascorbic acid) assists in the prevention of skinbruising and wound healing; vitamin E is an antioxidant; and copperassists in the treatment of elastic tissue defects. [Neldner, K. H.,Amer. Acad. Derm. Annl. Mtg., Wash. D.C., Dec. 6, 1993]. Topical use ofvitamin C is also believed to ward off sun damage, reduce breakdown ofconnective tissues, and possibly promote collagen synthesis. [Dial, W.,Medical World News, p. 12, March 1991]. Vitamin E is used topically asan anti-inflammatory agent, for enhancement of skin moisturization, forUV-ray protection of cells, and for retardation of premature skin aging.

Catechin-based preparations, including proanthanols andproanthocyanidins are powerful antioxidants. These compounds are foundin flowers, plant leaves, and grape seeds, for example. [Lubell, A.,Cosmetic Dermatol., 9(7):58 & 60 (July 1996)].

N-Acetylglucosamine and glucosamine have been examined for use in theprevention and treatment of degenerative joint diseases and cartilageloss, and found to increase the glycosaminoglycans present in thecartilage to restore cartilage. [See Grevenstein, J., et al., ActaOrthopaedia Belgica, 57(2):157-161 (1991); Setnikar, I., Drug Res.,36(4):720-733 (1986); Drovanti, A., et al, Clin. Therap., 3(4):1-6(1980)]. Glucosamine has also been examined in connection with arthritis[See, e.g., Murray, M. T.] and oral and injected glucosamine have beenreported to be useful for arthrosic patients. [Tapadinhas, M. J., etal., Pharmatherapeutica, 3(3):157-168 (1982); D'Ambrosio, E., et al.,Pharmatherapeutica, 2(8):504-508 (1981)].

The metabolism of glycosaminoglycans under the influence of herbal andother anti-inflammatory agents has been examined by measuringglycosaminoglycans in the skin, liver, kidney, and spleen afteradministration of several compounds. [Reddy, G. K., et al., Biochem.Pharmacology, 38(20) :3527-3534 (1989)].

In addition to their individual use to supplement a deficiency in apatient, various of the above ingredients have been combined to formpharmaceuticals designed to prevent and treat certain cellular, skin,and other conditions. For example, U.S. Pat. No. 3,773,930 discloses alow residue, dietary composition having at least one amino acid and aquantity of non-amino acid derived caloric material sufficient toobviate the diarrhea problem of straight amino acid compositions. Aflavoring material may also be included to render the composition morepalatable.

U.S. Pat. No. 4,285,964 discloses a salt of (+)-catechin formed byreacting (+)-catechin with at least a basic amino acid, such as L-lysineand L-arginine; and a hydrosoluble double salt formed from the reactionproduct of (+)-catechin with a basic amino-acid, such as L-lysine andL-arginine, and another inorganic or organic acid. The patent furtherdiscloses methods of treating degenerative diseases of the connectivetissue by topically administering the composition.

U.S. Pat. No. 4,414,202 discloses a composition for the treatment ofskin wounds with a buffered salt solution having a pH between 6 to 7.8and administering a starch hydrolysate compound, and preferablyincluding alphaketoglutaric acid or alphaketoglutarate salts. Optionaladditives to the composition include ascorbic acid or salts thereof,ferrous salts, and glycine, L-Proline, and L-Lysine.

U.S. Pat. No. 4,424,232 discloses a topical composition for thetreatment of herpes simplex, cold sores, lesions, and other painful skinconditions including L-lysine, gibberellic acid, and urea in an inertcarrier having water. The composition may also include L-ascorbic acid,as well as methyl paraben, propyl paraben, or mixtures thereof.

U.S. Pat. No. 4,647,453 discloses a method and composition for treatmentof tissue degenerative inflammatory disease in animals and humans byoral administration of ascorbic acid, bioavailable calcium, a precursoror stimulant of epinephrine or nor-epinephrine of tyrosine orphenylalanine, and an anti-inflammatory substance selected fromanti-inflammatory sugars, amino sugars and biocompatible acid additionsalts thereof, and anti-inflammatory amino acids, to promote connectivetissue regrowth.

U.S. Pat. No. 5,198,465 discloses a composition for treating precursordeficiencies in the synthesis of collagen with proline, glycine, lysine,vitamin C, and one or more compounds selected from α-ketoglutaric acid,methionine, cysteine, cystine, valine, and pharmaceutically acceptablediluents and excipients.

U.S. Pat. Nos. 5,332,579 and 5,308,627 disclose a nutritional supplementto assist persons recovering from addiction by administering a varietyof vitamins and minerals including enzyme activating substances such asmagnesium and zinc; an enzyme co-factor that is a vitamin like variousvitamin B complexes; an enzyme producer such as an amino acid likeglutamic acid; an herbal antispasmodic substance like Valerian root; andvitamin C.

U.S. Pat. No. 5,415,875 discloses a method of suppressing formation oflipid peroxide and removing peroxide by applying to the skin adecomposed product of shell membrane and tocopherol and derivatives.Lysine, proline, Vitamin C, for examples, are listed among a vast genusof optional additives.

The above references, however, do not teach pharmaceutical compositionsor methods for improving skin wrinkles along with other conditions, suchas skin elasticity and softness. Thus, it is desired to find apharmaceutical composition and a method for the prevention and treatmentof wrinkles and other skin conditions. The present inventionadvantageously provides pharmaceutical compositions, as well as methodsof treatment comprising the administration of such compositions, torepair skin for the prevention and treatment of wrinkles and other skindisorders.

SUMMARY OF THE INVENTION

The present invention relates to a pharmaceutical composition for theprevention and treatment of skin conditions in a patient having a sugarcompound that is converted to a glycosaminoglycan in the patient in anamount sufficient to thicken the skin, a primary antioxidant componentin an amount sufficient to substantially inhibit the activity ofcollagenase and elastase, at least one amino acid component in an amountsufficient to assist in the thickening of the skin, and at least onetransition metal component in an amount effective to bind collagen andelastic fibers and rebuild skin.

In one embodiment, the sugar compound is present in about 5 to 50 weightpercent, the primary antioxidant component is present in about 5 to 50weight percent, the amino acid component is present in about 8 to 60weight percent, and the transition metal component is present in about0.5 to 15 weight percent of the composition. In another embodiment, thesugar compound includes an N-acetylglucosamine compound or salt or esterthereof, the primary antioxidant component includes an ascorbic acidcomponent or salt or ester thereof, at least two amino acids selectedfrom the group of proline, lysine, cysteine, and methionine are present,and at least two the transition metal components including zinc,manganese or copper, or mixtures thereof, are present. In yet anotherembodiment, the composition further includes a pharmaceuticallyacceptable carrier or excipient.

In a more preferred embodiment, at least three transition metalcomponents are present, one of which is zinc monomethionine, one ofwhich is manganese ascorbate, and one of which is copper sebacate,wherein the zinc is present in about 10 to 30 weight percent of thecomplex and the manganese is present in about 5 to 20 weight percent ofthe complex, and the copper is present in about 5 to 20 weight percentof the complex. In another preferred embodiment, the N-acetylglucosamineis present in about 5 to 30 weight percent, the ascorbic acid is presentin about 5 to 50 weight percent, the amino acid comprises lysine andproline, wherein each is present in about 4 to 25 weight percent, andthe zinc monomethionine and the manganese ascorbate are each present inabout 1 to 10 weight percent and the copper sebacate is present in about0.1 to 5 weight percent of the composition.

In one preferred embodiment of the invention, the composition furtherincludes a catechin-based preparation, a glucosamine or apharmaceutically acceptable salt or ester thereof, and a chondroitin ora pharmaceutically acceptable salt or ester thereof. In a more preferredembodiment, the catechin-based preparation is a proanthanol orproanthocyanidin, and the glucosamine and chondroitin are each a sulfateor succinate. In a most preferred embodiment, the proanthocyanidin isgrape seed extract present in about 0.5 to 5 weight percent, theglucosamine is D-glucosamine sulfate present in about 3 to 17 weightpercent, wherein the glucosamine is about 60 to 90 weight percent of thesalt, and the chondroitin is chondroitin sulfate present in about 3 to17 weight percent of the composition, wherein the chondroitin ispreferably present as about 65 to 95 weight percent of the salt.

In another preferred embodiment, the composition further includes avitamin E source, a cysteine source, a vitamin B₃ source, quercetindihydrate, pyridoxal 5 phosphate-Co B₆, a methionine source, and avitamin A source. In a more preferred embodiment, the vitamin E isD-alpha tocopheryl acid succinate present in about 1 to 15 weightpercent, the vitamin B₃ is niacinamide present in about 0.5 to 15 weightpercent, the vitamin A is vitamin A palmitate present in about 0.1 to 5weight percent, the cysteine is N-acetyl cysteine present in about 1 to10 weight percent, the methionine is preferably L-selenomethioninepresent in about 0.1 to 5 weight percent, the quercetin dihydrate ispresent in about 0.5 to 15 weight percent, and the pyridoxal 5phosphate-Co B₆ is present in about 0.1 to 5 weight percent of thecomposition.

The invention further relates to a method for the prevention ortreatment of skin conditions, wherein the skin has a thickness of dermisand collagen, which includes administering the pharmaceuticalcomposition above in an amount therapeutically effective to modify thethickness of the skin to prevent or treat at least one skin condition.

In one embodiment according to the invention, the skin condition treatedis at least one of wrinkles, fine lines, thinning, reduced skinelasticity, reduced skin moisture, spider veins, senile purpura, sundamaged skin, aging skin, or rough skin. In another embodiment, thecomposition is administered orally. In a preferred embodiment, thecomposition is administered as a tablet or capsule having about 1 mg to2,000 mg of composition. In a more preferred embodiment, the tablet orcapsule has about 200 mg to 1,600 mg of composition, and in a mostpreferred embodiment, the tablet or capsule has about 600 mg to 1,000 mgof composition.

In another embodiment, the composition is administered in conjunctionwith concurrent or subsequent treatment by at least one additionalpharmaceutical composition for the prevention or treatment of a skincondition.

The ranges of the components of the pharmaceutical composition may vary,but the active ingredients should be understood to add to 100 weightpercent of the active pharmaceutical composition.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A formulation for the reduction of wrinkles and the improvement of otherskin conditions, such as increased skin elasticity and skin softness,has now been discovered. Moreover, the prevention or treatment ofunhealthy skin, such as aged skin or skin overexposed to sunlight, mayadvantageously be accomplished by the administration of thepharmaceutical composition of the present invention to a human in needof treatment. The pharmaceutical composition includes the combination ofa number of different components which interact to provide the desiredimprovements to the skin.

The advantageous pharmaceutical composition of the present inventionprevents and improves skin conditions by using a sufficient amount of atleast one sugar compound which is converted into glycosaminoglycans inthe bloodstream, in combination with other ingredients disclosed hereinto assist in thickening the dermis and supplementing collagen andelastic tissues. A thicker dermis desirably reduces the wrinkling andlines that occur when areas of the skin become thin. Various amino acidssuch as lysine, proline and cysteine assist in the thickening of thedermis, supplementing of collagen and elastic tissues and, consequently,reduction of wrinkles and other skin conditions. Additionally,antioxidants, such as vitamin C, inhibit collagenase and elastase,enzymes that break down collagen and elastic tissues. These antioxidantsassist in the prevention of additional wrinkles and facilitate thehealing of skin tissues. Finally, transition metal components areincluded to bind collagen fibers and inhibit elastase, an enzyme thatalso breaks down collagen and elastic tissue.

The composition preferably contains at least one sugar compound, andmore preferably just one sugar compound, present in about 5 to 50 weightpercent, preferably about 10 to 40 weight percent, and more preferablyabout 15 to 30 weight percent of the composition. The primaryantioxidant component is preferably present in an amount of about 5 to50 weight percent, more preferably about 10 to 40 weight percent, andmost preferably about 15 to 30 weight percent of the composition. Theamino acid component is preferably present in about 8 to 60 weightpercent, more preferably about 15 to 50 weight percent, most preferablyabout 20 to 40 weight percent of the composition. The transition metalcomponent is preferably present in about 0.5 to 15 weight percent, morepreferably present in about 2 to 12 weight percent, and most preferablypresent in about 5 to 10 weight percent of the composition.

The first component of the composition is any sugar compound that isconverted to glycosaminoglycans in the human bloodstream. Typically,this would be an N-acetylglucosamine compound, or a pharmaceuticallyacceptable salt or ester thereof. The N-acetylglucosamine component maybe N-acetylglucosamine or any pharmaceutically acceptable salt or esterthereof, but more preferably is the N-acetylglucosamine only. Thiscomponent must be present in sufficient quantity in the pharmaceuticalcomposition to promote thickening of the dermis. The N-acetylglucosamineis present in about 5 to 30 weight percent, preferably 8 to 27 weightpercent, and more preferably 12 to 24 weight percent of thepharmaceutical composition. A unit dose of N-acetylglucosamine istypically about 40 mg to 250 mg, preferably about 60 to 200, and morepreferably about 100 mg to 200 mg.

The pharmaceutical composition includes a primary antioxidant, whichtypically is a vitamin C source and preferably is ascorbic acid, or apharmaceutically acceptable salt or ester thereof, and more preferablyis ascorbyl palmitate, dipalmitate L-ascorbate, sodiumL-ascorbate-2-sulfate, or an ascorbic salt, such as sodium, potassium,or calcium ascorbate, or mixtures thereof. When oral formulations of thepharmaceutical composition are used, it is preferred that a non-acidicform of vitamin C be used to reduce the stomach irritation that mayoccur when using an acidic form. The vitamin C source is present in thepharmaceutical composition in about 5 to 50 weight percent, preferablyabout 7 to 40 weight percent, and more preferably about 10 to 25 weightpercent. A unit dose of this primary vitamin C source is typically about40 mg to 400 mg, preferably about 60 mg to 300 mg, and more preferablyabout 80 to 150 mg. Vitamin C is also approved by the FDA and has wideconsumer acceptance, so that it can be used in amounts as high as 10,000mg, if desired.

The pharmaceutical composition also includes at least one amino acid toassist in thickening the skin. Preferably two or more amino acids areused in combination. Either the L- or D- forms of amino acids areacceptable. Lysine and proline are the most preferred amino acids andare advantageously used in combination. Cysteine, methionine or otheramino acids can also be used, if desired. The amino acids may beincluded in a soluble form such as the hydrochloride, i.e., L-Lysinehydrochloride. The amino acids are present in an amount of about 2 to 25weight percent each, preferably about 4 to 20 weight percent each, andmore preferably about 6 to 15 weight percent each. A unit dose for eachamino acid is typically about 35 mg to 200 mg each, preferably about 50mg to 150 mg each, and more preferably about 70 mg to 120 mg in thepharmaceutical composition. Additional useful forms of amino acidinclude the following: a cysteine source, preferably N-acetyl cysteine,can be present in an amount of about 1 to 10 weight percent, preferablyabout 2 to 8 weight percent, and more preferably about 3 to 6 weightpercent of the pharmaceutical composition. A methionine source,preferably L-selenomethionine, can be present in an amount of about 0.1to 5 weight percent, preferably 0.2 to 3 weight percent, and morepreferably 0.3 to 1 weight percent of the composition, wherein theselenium component is between about 0.1 to 3 weight percent of themethionine source.

One or more transition metal compounds are included in an amounteffective to bind collagen and elastic tissue to rebuild the skin.Certain transition metal compounds inhibit the elastase enzyme toinhibit collagen and elastic tissue breakdown. Preferred transitionmetals include zinc, manganese and copper, with combinations thereofbeing most preferred.

A zinc component can be added to assist in binding collagen and elasticfibers, which both assists in the prevention of wrinkles and therebuilding of wrinkled skin. The zinc component may be any zinc compoundor pharmaceutically acceptable salt thereof, but more preferably is azinc complexed with an amino acid, and most preferably is zincmonomethionine, wherein the zinc is typically present in about 10 to 30weight percent of the complex. The zinc component is present in about 1to 10 weight percent, more preferably about 2 to 7 weight percent, andmost preferably about 3 to 5 weight percent of the pharmaceuticalcomposition.

A manganese component can also be added to assist in binding collagenand elastic fibers. The manganese component may be any manganesecompound or pharmaceutically acceptable salt thereof, but morepreferably is a manganese component which is at least partiallycomplexed with a vitamin C source, and most preferably is manganeseascorbate or manganese ascorbic acid, wherein the manganese is typicallypresent in about 5 to 20 weight percent of the complex. When complexedwith vitamin C, this vitamin C source may be included in the overallpercentage of vitamin C in the pharmaceutical composition. The manganesecomponent is present in about 1 to 10 weight percent, more preferablyabout 2 to 7 weight percent, and most preferably about 2.5 to 4 weightpercent of the pharmaceutical composition.

A copper component is preferably also included in the pharmaceuticalcomposition, and may be any copper compound or pharmaceuticallyacceptable salt thereof, but preferably is copper sebacate, wherein thecopper is typically present in about 5 to 20 weight percent of thecopper sebacate. The copper component also inhibits elastase and ispresent in about 0.1 to 5 weight percent, preferably about 0.2 to 3weight percent, and more preferably about 0.3 to 1 weight percent of thepharmaceutical composition. A unit dose of the pharmaceuticalcomposition may include about 1 mg to 40 mg, preferably about 2 mg to 25mg, and more preferably about 2.5 mg to 10 mg.

In a preferred form of the invention, the pharmaceutical compositionfurther includes a catechin-based preparation, such as a proanthanol orproanthocyanidin, along with glucosamine or a pharmaceuticallyacceptable salt or ester thereof, and chondroitin or a pharmaceuticallyacceptable salt or ester thereof.

The catechin-based preparation, similar to vitamin C, inhibits elastaseand collagenase, which is another enzyme that attacks elastic tissue andcollagen. The catechin-based preparation is preferably a proanthanol orproanthocyanidin, more preferably a proanthocyanidin, and mostpreferably grape seed extract. These compounds are considered to besecondary antioxidants, because they are present in lesser amounts thanthe primary antioxidant. The catechin-based preparation is present inabout 0.5 to 5 weight percent, more preferably about 0.6 to 3 weightpercent, and most preferably about 0.7 to 2 weight percent of thepharmaceutical composition.

The glucosamine or a pharmaceutically acceptable salt or ester thereof,and the chondroitin or a pharmaceutically acceptable salt or esterthereof are each present in about 3 to 17 weight percent, preferablyabout 4 to 12 weight percent each, and more preferably about 5 to 8weight percent each of the pharmaceutical composition. The glucosaminecomponent preferably is present as a sulfate or succinate, and morepreferably is D-glucosamine sulfate, wherein the glucosamine ispreferably present as about 60 to 90 weight percent of the salt. Theglucosamine content of this component contributes to the formation ofglycosoaminoglycans in the skin. The chondroitin component preferably ispresent as a sulfate or succinate, and more preferably is chondroitinsulfate, wherein the chondroitin is preferably present as about 65 to 95weight percent of the salt.

In a more preferred form, several optional additives are included in thepharmaceutical composition, such as a vitamin E source, a vitamin B₃source, quercetin powder, pyridoxal 5 phosphate-Co B₆, and a vitamin Asource. The vitamin E preferably is a sulfate or succinate vitamin Ecomplex, and more preferably is D-alpha tocopheryl acid succinate. Thevitamin E source is present in about 1 to 15 weight percent, preferablyabout 2 to 12 weight percent, and more preferably about 3 to 10 weightpercent of the composition. In any event, no more than 1,500 IU shouldbe ingested per day, as Vitamin E becomes toxic at higher doses. Thevitamin B₃ source preferably is niacinamide, and the source is presentin about 0.5 to 15 weight percent, preferably about 1 to 12 weightpercent, and more preferably about 1.5 to 10 weight percent of thecomposition. The vitamin A source preferably is vitamin A palmitate, andthe source is present in about 0.1 to 5 weight percent, preferably 0.2to 3 weight percent, and more preferably 0.3 to 1 weight percent of thecomposition. In the more preferred form, the amount of vitamin A dosageis about 500,000 IU/gram per unit dose. Vitamin A is toxic at highlevels, such that no more than 400,000 IU should be cumulativelyingested per day for greater than six months.

The quercetin powder is quercetin dihydrate, which is typically presentin about 0.5 to 15 weight percent, preferably about 1 to 12 weightpercent, and more preferably about 1.5 to 10 weight percent of thecomposition. The pyridoxal 5 phosphate-Co B₆, also known as P-5-Pmonohydrate, is typically present in about 0.1 to 5 weight percent,preferably 0.2 to 3 weight percent, and more preferably 0.3 to 1 weightpercent of the composition.

The phrase "therapeutically effective amount" means that amount of thepharmaceutical composition that provides a therapeutic benefit in thetreatment, prevention, or management of skin wrinkles and other skinconditions.

The magnitude of a prophylactic or therapeutic dose of the compositionin the acute or chronic management of wrinkles will vary with theseverity of the condition to be treated and the route of administration.The dose, and perhaps the dose frequency, will also vary according tothe age, body weight, and response of the individual patient. Ingeneral, the total daily dose range, for the conditions describedherein, is from about 10 mg to about 20,000 mg administered in single ordivided doses orally, topically, transdermally, or locally byinhalation. For example, a preferred oral daily dose range should befrom about 10 mg to 20,000 mg, more preferably about 2,000 mg to 16,000mg, and most preferably about 6,000 mg to 10,000 mg of the activecomponents (i.e., excluding excipients and carriers).

It is further recommended that children, patients aged over 65 years,and those with impaired renal or hepatic function initially receive lowdoses, and that they then be titrated based on individual response(s) orblood level(s). It may be necessary to use dosages outside these rangesin some cases, as will be apparent to those of ordinary skill in theart. Further, it is noted that the clinician or treating physician willknow how and when to interrupt, adjust, or terminate therapy inconjunction with individual patient response.

The term "unit dose" is meant to describe a single dose, although a unitdose may be divided, if desired. About 1 to 10 unit doses of the presentinvention are typically administered per day, preferably about 2 to 6doses per day, and more preferably about 4 doses per day.

Although any suitable route of administration may be employed forproviding the patient with an effective dosage of the compositionaccording to the methods of the present invention, oral administrationis preferred. Suitable routes include, for example, oral, rectal,parenteral, intravenous, topical, transdermal, subcutaneous,intramuscular, and like forms of administration may be employed.Suitable dosage forms include tablets, troches, dispersions,suspensions, solutions, capsules, patches, suppositories, and the like,although oral dosage forms are preferred.

The pharmaceutical compositions used in the methods of the presentinvention include the active ingredients described above, and may alsocontain pharmaceutically acceptable carriers, excipients and the like,and optionally, other therapeutic ingredients.

The term "pharmaceutically acceptable salt" refers to a salt preparedfrom pharmaceutically acceptable non-toxic acids or bases includinginorganic or organic acids. Examples of such inorganic acids arehydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric.Appropriate organic acids may be selected, for example, from aliphatic,aromatic, carboxylic and sulfonic classes of organic acids, examples ofwhich are formic, acetic, propionic, succinic, glycolic, glucuronic,maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic,mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic,pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, andgalacturonic. Examples of such inorganic bases, for potential saltformation with the sulfate or phosphate compounds of the invention,include metallic salts made from aluminum, calcium, lithium, magnesium,potassium, sodium, and zinc. Appropriate organic bases may be selected,for example, from N,N-dibenzylethylenediamine, chloroprocaine, choline,diethanolamine, ethylenediamine, meglumaine (N-methylglucamine), andprocaine.

The compositions for use in the methods of the present invention includecompositions such as suspensions, solutions and elixirs; aerosols; orcarriers such as starches, sugars, microcrystalline cellulose, diluents,granulating agents, lubricants, binders, disintegrating agents, and thelike, in the case of oral solid preparations (such as powders, capsules,and tablets), with the oral solid preparations being preferred over theoral liquid preparations. The most preferred oral solid preparations aretablets.

Because of their ease of administration, tablets and capsules representthe most advantageous oral dosage unit form, in which case solidpharmaceutical carriers are employed. If desired, tablets may be coatedby standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compound foruse in the methods of the present invention may also be administered bycontrolled release means and/or delivery devices such as those describedin U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and4,008,719, the disclosures of which are hereby incorporated byreference.

Pharmaceutical compositions for use in the methods of the presentinvention suitable for oral administration may be presented as discreteunits such as capsules, cachets, or tablets, or aerosol sprays, eachcontaining a predetermined amount of the active ingredient, as a powderor granules, as creams, pastes, gels, or ointments, or as a solution ora suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-wateremulsion, or a water-in-oil liquid emulsion. Such compositions may beprepared by any of the methods of pharmacy, but all methods include thestep of bringing into association the carrier with the active ingredientwhich constitutes one or more necessary ingredients. In general, thecompositions are prepared by uniformly and intimately admixing theactive ingredient with liquid carriers or finely divided solid carriersor both, and then, if necessary, shaping the product into the desiredpresentation.

For example, a tablet may be prepared by compression or molding,optionally, with one or more accessory ingredients. Compressed tabletsmay be prepared by compressing in a suitable machine the activeingredient in a free-flowing form such as powder or granules, optionallymixed with a binder, lubricant, inert diluent, surface active ordispersing agent. Molded tablets may be made by molding, in a suitablemachine, a mixture of the powdered compound moistened with an inertliquid diluent. Desirably, each unit dose, i.e., tablet, cachet orcapsule, contains from about 1 mg to 2,000 mg of the active ingredient,preferably about 200 mg to 1,600 mg, and more preferably about 600 mg to1,000 mg of the composition.

EXAMPLES

The invention is further defined by reference to the following examplesdescribing in detail the preparation of the compound and thecompositions used in the methods of the present invention, as well astheir utility. The examples are representative, and they should not beconstrued to limit the scope of the invention.

Example 1 Capsules

A large number of unit capsules are prepared by filling standardtwo-piece hard gelatin capsules each with the desired amount of powderedactive ingredient as described above, 150 milligrams of lactose, 50milligrams of cellulose, and 6 milligrams magnesium stearate.

Example 2 Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil,lecithin, cottonseed oil or olive oil is prepared and injected by meansof a positive displacement pump into gelatin to form soft gelatincapsules containing the desired amount of the active ingredient. Thecapsules are washed and dried for packaging.

Example 3 Tablets

A large number of tablets were prepared by conventional procedures sothat the dosage unit included: the desired amount of active ingredientas described herein, 50 milligrams of red beet root powder, 12milligrams of stearic acid, 10.95 milligrams of sorbitol, 3 milligramsof acdisol, 1 milligram of magnesium stearate, and 1 milligram ofsyloid. Appropriate coatings may be applied to increase palatability ordelay absorption. A specific therapeutic formulation of thepharmaceutical composition described herein is set forth in the tablebelow:

    ______________________________________                                                     Weight             Chemical or                                                Percent   Amount   Scientific Name                               Ingredient   (% w/w)   (mg)     (if different)                                ______________________________________                                        N-Acetylglucosamine                                                                        17.1      140      N-Acetyl D-                                                                   Glucosamine                                   Vitamin C (81.2%                                                                           15        123.2                                                  Ascorbic Acid)                                                                L-Lysine (80%)                                                                             12.2      100      L-Lysine                                                                      hydrochloride                                 L-Proline    11        90                                                     D-Glucosamine Sulfate                                                                      6.5       53.3                                                   (75%)                                                                         Chondroitin Sulfate                                                                        6.1       50                                                     (80%)                                                                         Vitamin E Succinate                                                                        4.3       39.7     D-α tocopheryl                                                          acid succinate                                Zinc monomethionine                                                                        3.7       30       Zinc DL-                                      (20%)                           methionine                                    N-Acetyl Cysteine                                                                          3.7       30                                                     Manganese Ascorbate                                                                        2.8       23.1                                                   (13% Mn)                                                                      Vitamin B.sub.3                                                                            2.4       20       Niacinamide                                   Niacinamide                                                                   Quercetin Powder                                                                           2.4       20       Quercetin                                                                     dihydrate                                     Grape Seed Extract                                                                         0.9       7.5      Proanthocyanidin                              Pyridoxal 5  0.6       5        P-5-P monohydrate                             Phosphate-Co B.sub.6                                                          Selenomethionine                                                                           0.5       4        L-                                            (0.5%)                          selenomethionine                              Vitamin A Palmitate                                                                        0.5       4                                                      (500,000 IU/GR)                                                               Copper Sebacate (14%)                                                                      0.4       2.9                                                    Red beet root powder                                                                       6.1       50       Beta vulgaris                                                                 rubra                                         Stearic acid 1.5       12                                                     Sorbitol     1.3       11                                                     Acdisol      0.4       3        Microcrystalline                                                              cellulose                                     Coconut oil  0.1       1        Magnesium                                                                     stearate                                      Syloid       0.1       1        Silicon dioxide                                                               (amorphous)                                   Total        820.7     100                                                    ______________________________________                                    

These tablets are an example of a preferred embodiment of a unit doseaccording to the present invention.

Examples 4-7 TESTING OF THE PRODUCT

The tablets of Example 3 were administered to test 73 female subjects todetermine the effects on the elasticity, firmness, and presence of finelines and wrinkles of the skin. A seven day conditioning period was usedprior to initiation of the study, where subjects were instructed todiscontinue use of all moisturizing products, sunscreens and liquidmake-ups, and to avoid excessive UV exposure and tanning salons.Subjects were permitted to use their current eye, powder blush, and lipproducts, and non-moisturizing soap.

Test subjects not in the control group, which consumed placebo tablets,consumed two (2) tablets of the test material of Example 3 daily withmeals. Before, and after two (2) and five (5) weeks of tablet use, thesubjects were measured as described below. Before measurements weretaken, all subjects were allowed to equilibrate for thirty minutes atapproximately 68° F. and 44 percent relative humidity. At eachmeasurement phase, three Corneometer readings, a negative impressionusing Silflo replicating material, and three Ballistometer and Cutometerreadings were made on the test sites indicated below.

A total of 65 subjects completed the study, as 7 discontinued the studyfor unrelated reasons and 1 developed a rash for 5 days. There were 12subjects in the control group and 53 using the tablets.

Example 4 Image Analysis

The texture of the skin, fine lines, and wrinkles were assessed bytaking Silflo replicas of the periorbital area (crow's feet) at each ofthe three test times. These negative impressions, or Silflo replicas,were illuminated at a precisely defined angle of 35° to create shadowsfor analysis by shades of gray. The skin topography is defined by the:(a) number of wrinkles; (b) total area of wrinkles; (c) total length ofwrinkles; (d) mean length of wrinkles; and (e) mean depth of wrinkles.The type of wrinkles was determined on the basis of depth, length, andarea.

As indicated in Table I below, the number of wrinkles were significantlyreduced by 34 percent (p<0.01) and the number of fine lines by 34percent (p<0.06) as a result of 5 weeks using the test material.

                                      TABLE I                                     __________________________________________________________________________    Number of Wrinkles and Fine Lines                                                      Number of Wrinkles                                                                            Number of Fine Lines                                          Mid-Baseline                                                                          Final-Baseline                                                                        Mid-Baseline                                                                          Final-Baseline                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                  __________________________________________________________________________    Average  -3  -7  -3  -15 -5  -4  -6  -12                                      Standard 9   13  13  12  6   10  14  10                                       Deviation                                                                     p value  p <0.41 p <0.01 p <0.96 p <0.06                                      % Difference                                                                           -11%                                                                              -19%                                                                              -6% -40%                                                                              -14%                                                                              -24%                                                                              -9% -43%                                     from Baseline                                                                 Total %  -8%     -34%    -10%    -34%                                         Difference (T - C)                                                            __________________________________________________________________________     T = Treated                                                                   C = Control                                                              

Example 4 indicates that use of tablets prepared by the formulation ofthe invention herein result in a 10 percent decrease in appearance ofwrinkles and an 8 percent decrease in fine lines after only 2 weeks oftreatment, and a decrease of 34 percent in both wrinkles and fine linesafter 5 weeks. Additionally, the observed degree of improvement is afunction of the length of treatment as indicated above. This stronglysuggests the treatment has imparted an improved skin infrastructure bybeneficially affecting the dermis of the skin.

Example 5 Ballistometer

The Ballistometer is an instrument designed to evaluate in vivo, in anon-invasive manner, the viscoelastic properties of the skin. Itanalyzes the bounce pattern displayed by a probe that is allowed toimpact on the skin. The kinetic energy of the probe striking the skin isstored by the elastic components of the skin and released back to makethe probe rebound to a lower height. The height to which the probe willrebound depends upon the amount of stored energy lost in shear viscositywithin the skin.

The capacity of the skin to absorb mechanical energy may thus bemeasured. Although it is unclear exactly which layer, or layers, of theskin are responsible, the mechanical properties of the dermis/epidermislayers are controlled by the density and geometry of the network ofcollagen fibers. It is believed the Ballistometer describes mostly thetissues underlying the stratum corneum.

Tests were conducted with the Ballistometer on one randomly chosen sideof the face, slightly below the cheek bone area. The height of firstrebound and the coefficient of restitution ("COR") were measured. TheCOR is the ratio of the first to the second rebound. Table II, below,indicates that the COR decreases by 10 percent (p<0.11) and the heightof the first rebound reduced by 18 percent (p<0.02) as a result of 5weeks use of the product. This indicates that less of the energy of thestriking probe was restored, thus, a greater amount of energy wasdissipated in the skin. This suggests the skin became softer and moreyielding during the test period.

                                      TABLE II                                    __________________________________________________________________________    Ballistometer Readings                                                                 Height of First Rebound (mm)                                                                  Coefficient of Restitution                                    Mid-Baseline                                                                          Final-Baseline                                                                        Mid-Baseline                                                                          Final-Baseline                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                  __________________________________________________________________________    Average  -0.16                                                                             -0.06                                                                             0.49                                                                              0.06                                                                              -0.02                                                                             0.00                                                                              0.01                                                                              0.00                                     Standard 0.41                                                                              0.48                                                                              0.52                                                                              0.51                                                                              0.03                                                                              0.02                                                                              0.03                                                                              0.03                                     Deviation                                                                     p value  p <0.56 p <0.02 p <0.06 p <0.11                                      % Difference                                                                           -6% 0%  22% 4%  -12%                                                                              -0% 12% 2%                                       from Baseline                                                                 Total %  6%      -18%    12%     -10%                                         Difference (T - C)                                                            __________________________________________________________________________     T = Treated                                                                   C = Control                                                              

Example 6 Cutometer

The Cutometer is a commercially available instrument (Courage & Khazaka,Germany) designed to measure the mechanical properties of the skin in anon-invasive manner. It measures the vertical deformation of the skin'ssurface when pulled by vacuum suction (500 mm Hg) through the smallaperture (2 mm) of a probe and the depth of penetration of the skin intothe probe optically with an accuracy of 0.01 mm. The probe is attachedto a computer, which completely controls probe operation and plots skindeformation as a function of time. From this curve, a number ofvariables can be extrapolated to estimate the elastic, viscoelastic, andpurely viscous behavior of the skin.

The following parameters were recorded: (a) the immediate distension(U_(e)) measured at 0.1 seconds; (b) the delayed distension (U_(v)); (c)the final distension (U_(f)), measured at 10 seconds; and (d) immediateretraction (U_(r)). The deformation parameters are extrinsic parametersdependent on skin thickness, and a variety of biologically importantratios were calculated: (a) U_(r) /U_(f), a measure of net elasticity ofthe skin; (b) U_(r) /U_(e), the biological elasticity, or measurement ofthe ability of the skin to regain its initial configuration afterdeformation; and (c) U_(v) /U_(e), the viscoelastic to elastic ratio,where an increase in this ratio indicates and increase in theviscoelastic portion of the deformation and/or a relative decrease ofthe elastic portion.

Tests were conducted using a Cutometer on both sides of the face on thecheek area. Table III, below, indicates that the delayed distension(U_(v)) decreased a significant 16 percent (p<0.04) after 5 weeks oftreatment. This parameter reflects viscoelastic properties of the skinand, thus, the behavior of the dermis. After 5 weeks, there were nostatistically significant changes in U_(e), the immediate distension,which is primarily affected by the moisture content and mechanicalproperties of the stratum corneum.

                                      TABLE III                                   __________________________________________________________________________    Cutometer Readings                                                            __________________________________________________________________________                 U.sub.f (mm)    U.sub.e (mm)                                                  Mid-Baseline                                                                          Final-Baseline                                                                        Mid-Baseline                                                                          Final-Baseline                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                              __________________________________________________________________________    Average      0.071                                                                             0.040                                                                             0.026                                                                             0.020                                                                             0.046                                                                             0.021                                                                             0.008                                                                             0.009                                Standard Deviation                                                                         0.038                                                                             0.058                                                                             0.058                                                                             0.049                                                                             0.028                                                                             0.042                                                                             0.048                                                                             0.043                                p value      p <0.11 p <0.71 p <0.08 p <0.96                                  % Difference from Baseline                                                                 39% 20% 16% 11% 36% 16% 11% 10%                                  Total % Difference (T - C)                                                                 -19%    -5%     -20%    -1%                                      __________________________________________________________________________                 U.sub.v (mm)    U.sub.r (mm)                                                  Mid-Baseline                                                                          Final-Baseline                                                                        Mid-Baseline                                                                          Final-Baseline                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                              __________________________________________________________________________    Average      0.026                                                                             0.020                                                                             0.018                                                                             0.010                                                                             0.033                                                                             0.017                                                                             0.013                                                                             0.008                                Standard Deviation                                                                         0.015                                                                             0.018                                                                             0.015                                                                             0.011                                                                             0.018                                                                             0.027                                                                             0.030                                                                             0.023                                p value      p <0.27 p <0.04 p <0.09 p <0.55                                  % Difference from Baseline                                                                 51% 39% 34% 19% 48% 26% 19% 15%                                  Total % Difference (T - C)                                                                 -12%    -16%    -22%    -5%                                      __________________________________________________________________________                 U.sub.r /U.sub.e                                                                              U.sub.v /U.sub.e                                              Mid-Baseline                                                                          Final-Baseline                                                                        Mid-Baseline                                                                          Final-Baseline                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                                                                           Control                                                                           Treated                              __________________________________________________________________________    Average      0.004                                                                             0.034                                                                             0.042                                                                             0.027                                                                             0.017                                                                             0.063                                                                             0.092                                                                             0.048                                Standard Deviation                                                                         0.105                                                                             0.064                                                                             0.062                                                                             0.064                                                                             0.073                                                                             0.078                                                                             0.132                                                                             0.073                                p value      p <0.21 p <0.45 p <0.08 p <0.13                                  % Difference from Baseline                                                                 2%  7%  9%  6%  8%  19% 28% 16%                                  Total % Difference (T - C)                                                                 5%      -3%     12%     -12%                                     __________________________________________________________________________                 U.sub.r /U.sub.r                                                              Mid-Baseline                                                                          Final-Baseline                                                        Control                                                                           Treated                                                                           Control                                                                           Treated                                              __________________________________________________________________________    Average      0.024                                                                             0.014                                                                             0.012                                                                             0.003                                                Standard Deviation                                                                         0.034                                                                             0.040                                                                             0.036                                                                             0.037                                                p value      p <0.47 p <0.46                                                  % Difference from Baseline                                                                 6%  4%  3%  1%                                                   Total % Difference (T - C)                                                                 -2%     -2%                                                      __________________________________________________________________________     T = Treated                                                                   C = Control                                                              

Example 7 Corneometer

The general appearance of soft, smooth skin depends largely on thepresence of an adequate amount of water in the stratum corneum. TheCorneometer is a commercially available instrument (Courage & Khazaka,Germany) to measure the changes in capacitance of the skin resultingfrom changes in the degree of hydration. It is particularly sensitive tolow levels of hydration, and uses measurements of arbitrary units ofskin hydration (H) to express capacitance.

Tests were conducted using a Corneometer on both sides of the face onthe cheek area. Changes in moisture content of the statum corneum occurrapidly due to changes in the environment, including hydration from theuse of moisturizing agents and humectants. Thus, the measurements withthe Ballistometer and Cutometer indicate changes occurred in deeperlayers of the skin, rather than the superficial stratum corneum. TableIV shows no significant changes in the hydration of the stratum corneumfollowing 2 weeks (p<0.84) and 5 weeks (p<0.67) of product use.

                  TABLE IV                                                        ______________________________________                                        Corneometer Readings                                                                     Skin Hydration (H)                                                            Mid-Baseline                                                                              Final-Baseline                                                    Control                                                                              Treated  Control  Treated                                   ______________________________________                                        Average      -5       -7       -8     -4                                      Standard Deviation                                                                         6         7        5     7                                       p value      p < 0.84      p < 0.67                                           % Difference from                                                                          -7%      -10%     -12%   -6%                                     Baseline                                                                      Total % Difference (T-C)                                                                   -3%           6%                                                 ______________________________________                                         T = Treated                                                                   C = Control                                                              

Various modifications of the invention in addition to those shown anddescribed herein will be apparent to those skilled in the art from theforegoing description. Such modifications are also intended to fallwithin the scope of the appended claims. The foregoing disclosureincludes all the information deemed essential to enable those skilled inthe art to practice the claimed invention.

What is claimed is:
 1. An orally administered pharmaceutical compositionfor the prevention and treatment of skin conditions in a patientcomprising:a sugar compound that is converted to a glycosaminoglycan inthe patient in an amount sufficient to thicken the skin; a primaryantioxidant component in an amount sufficient to substantially inhibitthe activity of collagenase and elastase; at least one amino acidcomponent in an amount sufficient to assist in the thickening of theskin; and at least one transition metal component in an amount effectiveto bind collagen and elastic fibers and thicken skin.
 2. Thepharmaceutical composition of claim 1, wherein the sugar compound ispresent in about 5 to 50 weight percent, the primary antioxidantcomponent is present in about 5 to 50 weight percent, the amino acidcomponent is present in about 8 to 60 weight percent, and the transitionmetal component is present in about 0.5 to 15 weight percent of thecomposition.
 3. The pharmaceutical composition of claim 1, wherein thesugar compound comprises an N-acetylglucosamine compound or salt orester thereof, the primary antioxidant component comprises ascorbic acidcompound or salt or ester thereof, at least two amino acids selectedfrom the group consisting of proline, lysine, cysteine, and methionineare present, and at least two the transition metal components comprisingzinc, manganese or copper, or mixtures thereof, are present.
 4. Thepharmaceutical composition of claim 3, wherein at least three transitionmetal components are present, one of Which is zinc monomethionine, oneof which is manganese ascorbate, and one of which is copper sebacate,wherein the zinc is present in about 10 to 30 weight percent of thecomplex and the manganese is present in about 5 to 20 weight percent ofthe complex, and the copper is present in about 5 to 20 weight percentof the complex.
 5. The pharmaceutical composition of claim 3, whereinthe N-acetylglucosamine is present in about 5 to 30 weight percent, theascorbic acid is present in about 5 to 50 weight percent, the amino acidcomponent comprises lysine and proline, wherein each is present in about4 to 25 weight percent, and the zinc monomethionine and the manganeseascorbate are each present in about 1 to 10 weight percent and thecopper sebacate is present in about 0.1 to 5 weight percent of thecomposition.
 6. The pharmaceutical composition of claim 1, wherein thecomposition further comprises a pharmaceutically acceptable carrier orexcipient.
 7. The pharmaceutical composition of claim 1, furthercomprising a vitamin E source, a cysteine source, a vitamin B₃ source,quercetin dihydrate, pyridoxal 5 phosphate-Co B₆, a methionine source,and a vitamin A source.
 8. The pharmaceutical composition of claim 7,wherein the vitamin E is D-alpha tocopheryl acid succinate present inabout 1 to 15 weight percent, the vitamin B₃ is niacinamide present inabout 0.5 to 15 weight percent, the vitamin A is vitamin A palmitatepresent in about 0.1 to 5 weight percent, the cysteine is N-acetylcysteine present in about 1 to 10 weight percent, the methionine ispreferably L-selenomethionine present in about 0.1 to 5 weight percent,the quercetin dihydrate is present in about 0.5 to 15 weight percent,and the pyridoxal 5 phosphate-Co B₆ is present in about 0.1 to 5 weightpercent of the composition.
 9. A method for the prevention or treatmentof skin conditions, wherein the skin has a thickness of dermis andcollagen, which comprises administering to a patient:a sugar compoundthat is converted to a glycosaminoglycan in the patient in an amountsufficient to thicken the skin; a primary antioxidant component in anamount sufficient to substantially inhibit the activity of collagenaseand elastase; at least one amino acid component in an amount sufficientto assist in the thickening of the skin; and at least one transitionmetal component in an amount effective to bind collagen and elasticfibers and thicken skin, so as to modify the thickness of the skin toprevent or treat at least one skin condition.
 10. The method of claim 9,wherein the skin condition prevented or treated is at least one ofwrinkles or the appearance thereof, fine lines or the appearancethereof, thinning, reduced skin elasticity, reduced skin moisture,spider veins, senile purpura, sun damaged skin, aging skin or roughskin.
 11. The method of claim 9, wherein the sugar, the primaryantioxidant, the at least one amino acid component, and the at least onetransition metal component are administered simultaneously as apharmaceutical composition.
 12. The method of claim 11, wherein thecomposition is administered in conjunction with concurrent or subsequenttreatment by at least one additional pharmaceutical composition for theprevention or treatment of a skin condition.
 13. A method for theprevention or treatment of skin conditions, wherein the skin has athickness of dermis and collagen, which comprises administering to apatient:a sugar compound that is converted to a glycosaminoglycan in thepatient in an amount sufficient to thicken the skin; a primaryantioxidant component in an amount sufficient to substantially inhibitthe activity of collagenase and elastase; at least one amino acidcomponent in an amount sufficient to assist in the thickening of theskin; at least one transition metal component in an amount effective tobind collagen and elastic fibers and thicken skin; and a catechin-basedcomponent present in an amount sufficient to inhibit the presence of ananti-collagen enzyme in the skin, so as to modify the thickness of theskin to prevent or treat at least one skin condition.
 14. Anpharmaceutical composition for the prevention and treatment of skinconditions in a patient consisting essentially of:a sugar compound thatis converted to a glycosaminoglycan in the patient in an amountsufficient to thicken the skin; a primary antioxidant component in anamount sufficient to substantially inhibit the activity of collagenaseand elastase; at least one amino acid component in an amount sufficientto assist in the thickening of the skin; and at least one transitionmetal component in an amount effective to bind collagen and elasticfibers and thicken skin.